Investor relations

Investor relations

Our science-led strategy is key to delivering long-term value for patients, employees and shareholders.

NYSE: MRK
June 7, 2026 4:41 am ET
Delayed at least 20 minutes

View stock information

Latest news, events & financials

June 4, 2026

Merck Animal Health Reinforces Commitment to Help Protect U.S. Livestock from New World Screwworm Threat

June 2, 2026

Merck to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

June 1, 2026

Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA® (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting

View all

June 04, 2026

Webcast

Jefferies Global Healthcare Conference

Webcast Transcript

June 01, 2026

Webcast

Investor Event at ASCO 2026

Webcast Presentation Transcript

May 26, 2026

Webcast

2026 Annual Meeting of Shareholders

Webcast Presentation Vote Results Transcript

April 30, 2026

Earnings

Q1 2026 Earnings Call

Webcast 1Q26 Merck Earnings Presentation 1Q26 Merck Earnings Announcement 1Q26 Merck Other Financial Disclosures Transcript Form 10-Q 1Q26 Other Financial Disclosures (Excel) 1Q26 Prepared Remarks

March 25, 2026

Webcast

Merck to Acquire Terns Pharmaceuticals

Webcast Presentation Transcript

March 03, 2026

Webcast

TD Cowen 46th Annual Health Care Conference

Webcast Transcript

February 03, 2026

Earnings

Q4 2025 Earnings Call

Webcast 4Q25 Merck Earnings Presentation 4Q25 Merck Earnings Announcement 4Q25 Merck Other Financial Disclosures Transcript Form 10-K 4Q25 Other Financial Disclosures (Excel) 4Q25 Prepared Remarks

January 12, 2026

Webcast

44th Annual J.P. Morgan Healthcare Conference

Webcast Transcript Presentation

View all

1Q26 Merck Earnings Presentation

1Q26 Merck Other Financial Disclosures

1Q26 Other Financial Disclosures (Excel)

1Q26 Prepared Remarks

47th Annual Goldman Sachs Global Healthcare Conference

June 9, 2026

Merck office building and research site in South San Francisco

Add to Calendar

Webcast

See full agenda

Our pipeline shows our relentless pursuit of the next breakthrough.

Explore our pipeline

Phase II programs

50+

Phase III programs

30+

Under review

Illustration of leaders speaking on stage

Our leadership

Our deep bench of talent has the knowledge, commitment and expertise to successfully execute on our innovation strategy.

Leadership

Image showing microbes in a lab dish on the left and earth on the right

Sustainability

Supporting the future of our business and the health and well-being of patients, people and communities around the world.

Purpose for Progress Impact Report 2024/2025

Download our Sustainability financing documents:

2023 Sustainability bond allocation report

2022 Sustainability bond allocation report

We're led by our science

We follow the science to our next breakthrough, leaving no stone unturned.

View our stories

Innovation

Our Q1 2025 financial results

Merck’s (NYSE: MRK) Q1 2025 results reflect strong progress, including increasing contributions from newer medicines and vaccines. Our company announced Q1 worldwide sales of $15.5 billion. “Our company made strong progress to start the year, with increasing contributions from our newer commercialized medicines and vaccines and continued advancement of our pipeline,” said Rob Davis, chairman […]

illustration of people on top of hexagon shapes

Innovation

Our Q4 and full-year 2024 financial results

Merck’s (NYSE: MRK) Q4 and full-year 2024 results reflect strong growth. Our company announced Q4 worldwide sales of $15.6 billion, an increase of 7% from Q4 2023. Full-year 2024 worldwide sales were $64.2 billion, an increase of 7% from full-year 2023. “We delivered strong growth in 2024, reflecting demand for our innovative portfolio, including […]

Two people interacting with a bar graph made

Innovation

Our Q3 2024 financial results

Merck’s (NYSE: MRK) Q3 2024 financial results represent strong progress across the business and our diverse pipeline. Our company announced worldwide sales of $16.7 billion, an increase of 4% from Q3 2023. “Our third-quarter results were strong, as we continue to make progress heading into 2025 and beyond,” said Rob Davis, chairman and chief executive officer. […]

Innovation

Our Q1 2025 financial results

Next: Our Q1 2025 financial results

Innovation

Our Q4 and full-year 2024 financial results

Next: Our Q4 and full-year 2024 financial results

Innovation

Our Q3 2024 financial results

Next: Our Q3 2024 financial results

Unsubscribe from email alerts

For questions, please contact our team.

Who we are